Breast Cancer Oncology
Sep 19, 2022
Patients with triple-negative breast cancer (TNBC) who harbor more than 40% tumor-infiltrating lymphocytes in their tumor respond well to neoadjuvant immune checkpoint blockade, results from the phase...
Sep 14, 2022
Results from the second interim analysis of MONARCH 3 show that overall survival is numerically longer with abemaciclib plus a non-steroidal aromatase inhibitor (NSAI) versus placebo plus a NSAI in th...
Aug 16, 2022
Click to read this study in The Lancet Oncology. ...
Aug 10, 2022
Click to read this study in JAMA Oncology. ...
Aug 05, 2022
Click to read this study in The Lancet Oncology. ...
Jul 28, 2022
Click to read this study in JAMA. ...
Jul 21, 2022
Click to read this study in JAMA Network Open. ...
May 19, 2022
Click to read this study in Journal of Clinical Oncology. ...
May 04, 2022
Click to read this study in The Lancet Oncology. ...
Apr 05, 2022
Click to read this study in JAMA Oncology. ...
Dec 15, 2021
In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positive/HER2-neg...
Dec 15, 2021
According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with ER-positi...
Dec 15, 2021
Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy follow...
Dec 15, 2021
A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial, it provid...
Dec 15, 2021
Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows no benefit...
Dec 15, 2021
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of...
Dec 15, 2021
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings in ER-posi...
Dec 15, 2021
Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...
Dec 15, 2021
Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...
